|
| Press Releases |
|
 |
|
| Tuesday, April 1, 2025 |
|
|
Eisai to Divest Rights for Pariet in China to Peak Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. more info >> |
|
| Thursday, March 27, 2025 |
|
|
エーザイ、アルツハイマー・パーキンソン病学会において、レカネマブの長期実臨床データやバイオマーカーをはじめとするアルツハイマー病の最新成果を発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗 Aβプロトフィブリル＊抗体レカネマブ（一般名、製品名「レケンビ®」、米国ブランド名「LEQEMBI」）をはじめとする当社のアルツハイマー病（AD）ポートフォリオに関する最新研究成果について、口頭発表６演題を含む合計 16 演題を、4 月 1 日から 5 日までオーストリア・ウィーンおよびバーチャルで開催される「アルツハイマー・パーキンソン病学会において発表することをお知らせします。 more info >> |
|
| Tuesday, March 25, 2025 |
|
|
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards |
| Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (early AD ) has received the Prime Minister's Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). more info >> |
|
|
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Eisai Co., Ltd. announced today that it has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Nadeshiko Brand 2025 as a listed company excelling in the promotion of women in the workplace. more info >> |
|
|
エーザイ、日本発 世界初の早期アルツハイマー病治療剤「レケンビ」が第 12 回技術経営・イノベーション大賞において「内閣総理大臣賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、一般社団法人科学技術と経済の会（JATES*）が主催する第 12 回技術経営・イノベーション大賞において、早期アルツハイマー病（早期 AD**）を適応とする、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ®」（一般名：レカネマブ）が「内閣総理大臣賞」を受賞しましたのでお知らせします。 more info >> |
|
| Monday, March 24, 2025 |
|
|
エーザイ、女性活躍推進に優れた上場企業として令和 6 年度「なでしこ銘柄」に2 回目の選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、女性活躍推進に優れた上場企業として、経済産業省と東京証券取引所より、令和 6 年度「なでしこ銘柄」に選定されたことをお知らせします。2 年連続の選定となります。 more info >> |
|
| Monday, March 10, 2025 |
|
|
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time |
| Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective. more info >> |
|
|
エーザイ、「健康経営銘柄2025」に初選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、本日、当社が従業員の健康管理を経営的な視点から考え、戦略的に取り組んでいる企業として、経済産業省と東京証券取引所が共同で実施する「健康経営銘柄 2025」に初めて選定されたことをお知らせします。 more info >> |
|
| Wednesday, March 5, 2025 |
|
|
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan |
| Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
'Talon Academy' Triumphs as RoV Championship After Intense Battle Against 'Dream' at the depa ESPORTS TOURNAMENT Grand Final
Jun 18, 2025 01:00 HKT/SGT
|
|
|
ICDM: Boards Must Be Held to the Highest Standards of Rigour and Accountability, with Expectations to 'Be More' Visionary, Resilient and Engaged
Jun 18, 2025 00:30 HKT/SGT
|
|
|
Hola Prime Enhances Trader Edge with Powerful FX Replay Backtesting Tool
Jun 17, 2025 23:00: JST
|
|
|
CITIC Telecom CPC Clinches Silver Medal at the 50th International Exhibition of Inventions Geneva
Jun 17, 2025 22:54 HKT/SGT
|
|
|
Hola Prime Enhances Trader Edge with Powerful FX Replay Backtesting Tool
Jun 17, 2025 22:00 HKT/SGT
|
|
|
Transoft Solutions Acquires CGS Labs
Jun 17, 2025 20:36 HKT/SGT
|
|
|
Transoft Solutions 收購 CGS Labs
Jun 17, 2025 20:35 HKT/SGT
|
|
|
How Containers Supercharge AI Development Projects
Jun 17, 2025 20:00 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates 135 Years at Pitti Uomo 108 with the Spring-Summer 2026 Collection and a Spectacular Anniversary Event at Santa Maria Novella in Florence
Jun 17, 2025 20:00 HKT/SGT
|
|
|
Tianci International: Empowering global logistics and shipping, facilitating efficient supply chain circulation
Jun 17, 2025 19:00: JST
|
|
|
CaoCao Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Jun 17, 2025 18:22 HKT/SGT
|
|
|
曹操出行宣佈於香港聯交所主板上市計劃
Jun 17, 2025 18:00 HKT/SGT
|
|
|
Tianci International: Empowering global logistics and shipping, facilitating efficient supply chain circulation
Jun 17, 2025 18:00 HKT/SGT
|
|
|
Transoft Solutions Acquires CGS Labs
Jun 17, 2025 17:00: JST
|
|
|
Honda Celebrates 60th Anniversary of First F1 Victory with Special Events Program
Jun 17, 2025 17:45 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
